India, Sept. 11 -- Glenmark Specialty S.A., a wholly-owned subsidiary of Mumbai-based Glenmark Pharmaceuticals, has announced the launch of RYALTRIS(R) Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.

The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) earlier this year.

Allergic rhinitis is a highly prevalent chronic condition in Brazil, affecting an estimated 20-30% of the population, equivalent to nearly 40-60 million people2,3. This significant disease burden highlights the need for effective, convenient, and differentiated treatme...